Ligand Pharma (LGND) Receives a Buy from Bank of America Securities
TipRanks (Thu, 28-May 6:59 AM ET)
Ligand to Participate in June Investor Conferences
Globe Newswire (Wed, 27-May 4:01 PM ET)
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Globe Newswire (Tue, 12-May 4:18 PM ET)
Ligand Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 7:00 AM ET)
Globe Newswire (Wed, 6-May 8:01 AM ET)
Ligand to Participate in May Investor Conferences
Globe Newswire (Tue, 5-May 4:01 PM ET)
Business Wire (Tue, 28-Apr 12:45 PM ET)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
PRNewswire (Mon, 27-Apr 3:06 PM ET)
Globe Newswire (Mon, 27-Apr 7:00 AM ET)
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Globe Newswire (Wed, 22-Apr 7:00 AM ET)
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals trades on the NASDAQ stock market under the symbol LGND.
As of May 28, 2026, LGND stock price declined to $235.61 with 54,117 million shares trading.
LGND has a beta of 0.84, meaning it tends to be less sensitive to market movements. LGND has a correlation of 0.09 to the broad based SPY ETF.
LGND has a market cap of $4.72 billion. This is considered a Mid Cap stock.
Last quarter Ligand Pharmaceuticals reported $52 million in Revenue and $1.63 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.01.
In the last 3 years, LGND traded as high as $247.38 and as low as $49.24.
The top ETF exchange traded funds that LGND belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
LGND has outperformed the market in the last year with a price return of +131.8% while the SPY ETF gained +28.9%. LGND has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +18.8% and +6.5%, respectively, while the SPY returned +10.3% and +1.7%, respectively.
LGND support price is $229.37 and resistance is $242.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGND shares will trade within this expected range on the day.